Omeros (NASDAQ:OMER) Shares Down 3.1% – Here’s Why

Shares of Omeros Co. (NASDAQ:OMER) fell 3.1% on Monday . The stock traded as low as $10.61 and last traded at $10.86. 44,701 shares traded hands during trading, a decline of 90% from the average session volume of 459,604 shares. The stock had previously closed at $11.21.

Analyst Ratings Changes

Several research firms have recently weighed in on OMER. Rodman & Renshaw began coverage on Omeros in a research note on Thursday, November 14th. They set a “buy” rating and a $9.00 price target for the company. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research note on Thursday, December 19th. RODMAN&RENSHAW upgraded Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. D. Boral Capital began coverage on Omeros in a research note on Monday, December 23rd. They set a “buy” rating and a $36.00 price target for the company. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $22.50.

Omeros Trading Down 4.0 %

The company has a market capitalization of $623.54 million, a PE ratio of -4.66 and a beta of 2.01. The stock has a fifty day moving average of $8.32 and a two-hundred day moving average of $5.63.

Institutional Investors Weigh In On Omeros

Hedge funds have recently made changes to their positions in the company. Barclays PLC boosted its position in shares of Omeros by 121.3% during the third quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock valued at $376,000 after purchasing an additional 51,873 shares in the last quarter. State Street Corp boosted its position in shares of Omeros by 0.3% during the third quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock valued at $4,867,000 after purchasing an additional 3,839 shares in the last quarter. HighTower Advisors LLC boosted its position in shares of Omeros by 7.2% during the third quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 4,000 shares in the last quarter. MML Investors Services LLC boosted its position in shares of Omeros by 19.2% during the third quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 3,000 shares in the last quarter. Finally, Wellington Management Group LLP bought a new stake in Omeros in the third quarter worth $305,000. 48.79% of the stock is currently owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.